The drugmaker is one step closer to a potential approval of its experimental cancer treatment.
Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.
Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Valeant added 250 primary care sales reps to promote its Salix portfolio.
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.
"In Australia, we are the healthcare industry," he says.
The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.
The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.
If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.
Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.
But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.
BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.
With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?
Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle